The choice of cell type, culture conditions, and endpoint all affect the result
Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST et al (2004)
Stable Gastric Pentadecapeptide BPC 157 research protocol of Rat Glaucoma [PMID: 35052769] Laboratory literature summary: Stable Gastric Pentadecapeptide BPC 157 research protocol of Rat Glaucoma
However, despite their significant therapeutic potential in cancer treatment, it is essential to also focus on managing immune-related adverse events (irAEs)
Notably, compound 1d exhibited the most potent activity against Escherichia coli and Staphylococcus aureus with MIC ranges of 31.3125.0 g/mL and against Pseudomonas aeruginosa with MIC ranges of 375.0500.0 g/mL